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Detection of abnormal peripheral blood mononuclear cell cytokine
networks in human IgA nephropathy. Dysregulated cytokine expression
has been implicated in the pathogeneis of IgA nephropathy, but the
mechanisms and selectivity of this response are poorly understood. In
this study we have examined the expression of a range of immunoreg-
ulatory cytokine mRNAs by peripheral blood mononuclear cells
(PBMNCs) from 45 patients with igA nephropathy stratified empirically
according to urinary red cell excretion: 10 in remission, and 35 with
active disease (21 mild, 14 moderate), and 17 normal, and 15 disease,
controls. We used a semi-quantitative polymerasc chain reaction (PCR)
technique. None of the patients had experienced recent episodes of
macroscopic hematuria. Simultaneous analysis of monocyte class 11
antigen (DR) expression was also performed by two-color immunoflow
cytometry. TGF-/3l mRNA was detected in 68% (24 of 35) of patients
with active, and 70% (7 of 10) inactive IgA nephropathy, but in only
18% (3 of 17) normal (P < 0.005), and 27% (4 of 15) disease controls.
IL-6 transcripts were identified in 37% (13 of 35) of patients with active
IgA nephropathy, compared with 6% (1 of 17) normal controls (P =
0.015), with no significant increase in IgA remission, or disease control
groups. TNF-a mRNA was detected in 29% (5 of 17) of normal and 53%
(8 of 15) disease controls, but in only 7% (3 of 35) of patients with IgA
nephropathy (P = 0.015). There was no significant change in TGF-/32,
4FN, IL-2, IL-4, IL-I a or IL-l/3 detection between groups. There was
an association between y-IFN and IL-6 mRNA detection in patients
with active IgA nephropathy: 83% (5 of 6) with y-IFN transcripts also
had detectable IL-6 mRNA, compared with 28% (8 of 29) of those
without y-IFN transcripts (P = 0.01). There was also phenotypic
evidence of cellular activation, with an increased percentage of mono-
cytes expressing high levels of class II antigen in patients with moder-
ately active nephropathy, mean (SD), 12.6 (4.8)%, compared with
normal, 6.7 (l.6)% (P < 0.001), and disease controls, 7.5 (5.2)%.
Furthermore, class II antigen expression was significantly higher in IgA
nephropathy patients with detectable IL-6, 12.4 (5. 1)%, and in partic-
ular, y-IFN mRNA, 14.3 (6.8)%, as opposed to those without detectable
mRNA species, 8.8 (3.8)%, and 9.2 (3.7)%, respectively (P 0.02).
These data suggest there is an abnormal interactive network of mono-
cyte and T cell derived cytokines, associated with monocyte activation,
in peripheral blood MNCs from patients with IgA nephropathy. This
may have important implications for the pathogenesis of immune
system abnormalities, renal cell injury and scar tissue formation in this
disease.
Primary IgA nephropathy is a chronic, and often relapsing
form of nephritis, characterized by the mesangial deposition of
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immunoglobulins A and 0, matrix expansion, and cellular
proliferation [1]. It is associated with abnormalities in both
systemic [2—4], and mucosal [5] IgA immune systems, with
episodic secretion of IgA and G antibodies demonstrating
characteristic autoimmune recognition profiles [6—8]. Glomeru-
lar deposition of immunoglobulin alone is, however, insufficient
to explain the expression of renal pathology in this condition.
This is exemplified by the recent description of a series of
patients with IgA nephropathy in whom the clinical presenta-
tion with macroscopic hematuria and proteinuria preceded
renal immunoglobulin deposition [91.
Isolated studies have demonstrated that cultured peripheral
blood MNCs from patients with IgA nephropathy have the
capacity to secrete high levels of the cytokines interleukin
(IL)-2 [10, 11], y-interferon (IFN) [11] and IL-6 [12, 13], which
may have a direct impact on lymphocyte function and immu-
noglobulin secretion [14]. Mononuclear cells (MNC) have a
central role in host response to infecting pathogenetic organ-
isms, and there is also evidence of abnormal renal trafficking of
MNC in these patients, with the accumulation of infiltrating
mononuclear phagocytes during active disease [15, 16]. While
the deposition of nephritogenic antibodies may be involved in
one limb of this process [6, 7], cellular depletion studies indicate
that these cells may be important mediators of glomerular injury
[17—19]. This process is likely to involve the secretion of a range
of cytokines by activated infiltrating MNCs, as these are known
to exert paracrine effects on both endothelial [201, and mesan-
gial cell types [21]. Furthermore, in vitro studies demonstrate
that endotoxin stimulated monocytes secrete soluble factors
which induce marked proliferative [22], and secretory [23]
responses in cultured mesangial cell monolayers. In addition,
mesangial expression of cytokines such as tumor necrosis
factor (TNF)-a, IL-6, and transforming growth factor (TGF)-f3,
which are also secreted in high concentrations by activated
monocytes, are autoinduced [21, 24, 25]. Evidence for this
process in vivocomes from studies using anti-cytokine blocking
antibodies [26—28], or with the exogenous administration of
recombinant cytokines [29, 30], in which these manipulations
have significantly modulated glomerular injury in experimental
nephropathies. In human disease we identified enhanced tissue
expression of IL-6, and other mRNAs [31], and IL-6 protein
[32] in the glomeruli and renal interstitium of patients with IgA
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nephropathy, with increased urinary IL-6 excretion associated
with disease activity [33, 34].
The mechanism and balance of MNC cytokine expression in
IgA nephropathy is, however, poorly understood. Isolated
study of T cell or monocyte derived factors fails to account for
the complex interactive network of secreted cytokines which
are operative in vivo, and it is unclear whether there is a
generalized or selective dysregulation of cytokine expression in
this condition. Furthermore, while the secretion of cytokines
IL-2, y-IFN and IL-6 in cell culture supernatants may reflect
endogenous activation of circulating MNCs in vivo, it may
equally represent an ex vivo artifact associated with cell manip-
ulation in culture [35, 36]. The aim of this study was, therefore,
to determine whether there is endogenous dysregulation of
cytokine expression and cellular activation in MNCs from
patients with IgA nephropathy in the context of a network of
lymphocyte and monocyte derived factors.
Methods
Patients and controls
We studied 45 patients with primary IgA nephropathy, 31
male, 14 female, age [mean (SD)] 42 (13.8) years. These were
empirically stratified according to urinary red cell excretion: 10
in remission (<8 RBCs/mm3 urine), 35 with active disease,
comprising 21 mild (8 to 100 RBCsImm3 urine) and 14 with
moderate disease activity (>100 RBCs/mm3 urine). There were
also 15 disease controls, 7 male, 9 female, age 41.9(13.8) years,
7 with non-IgA (1gM) mesangial proliferative GN (MPGN), and
8 with chronic renal failure (CRF) of non-immune' etiology, 5
due to chronic pyelonephritis, and 3 with hypertensive nephro-
sclerosis. In addition there were 17 healthy volunteers, 11 male,
6 female, age 41.9 (13.8) years, serving as normal controls.
Serum creatinine levels and 24-hour urinary protein excretion
were determined simultaneously (Fig. 1). All patients had stable
renal function (<15% increase in serum creatinine over 12
months), negative serology for systemic lupus erythematosis,
and had no clinical evidence of systemic or hepatic disease.
Among the patients with active IgA nephropathy, 22 had the
clinical picture of persistent or intermittent microscopic hema-
turia, and 13 a pattern of relapsing macroscopic urinary blood
loss. None had experienced recent episodes of macroscopic
hematuria at the time of study (2 months), and none of the
patients or controls had received immunosuppressive therapy
or steroids prior to the study.
Sample preparation and cell culture
Peripheral blood MNCs were isolated from heparinized ve-
nous blood using a standard ficoll/metrizoate gradient (Lym-
phoprep, Nycomed Pharma, Norway), and the cell pellet
washed in PBS for subsequent analysis. As a positive control,
10 ml of fresh, anticoagulated peripheral venous blood were
incubated in 25 ml screw cap siliconized glass bottles ('Repel-
cote', BDH, UK), with 1 j.tg/ml of lipopolysaccharide (LPS) (E.
coli, Olll:B4; Sigma Chemicals, UK), sealed after exposure to
5% CO2 humidified incubator for 15 minutes, and placed on a
blood roller at 50 rpm at 37°C for two to six hours prior to MNC
separation.
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Fig. 1. Serum creatinine and urinary protein excretion in controls and
patient groups. There were significant differences in serum creatinine(P = 0.0001) and urinary protein (P = 0.0004) excretion between groups
(P <0.0005; Kruslcal-Wallis). (—) represents median values; * indicates
comparison with normal controls, P < 0.01 (Mann-Whitney U test).
Analysis of mononuclear cell RNA
RNA isolation and reverse transcription (RT). Total MNC
RNA was isolated using a modified guanidine hydrochloride!
phenol extraction procedure [37]. Initially, cellular viability was
determined by Trypan blue exclusion (>95%), and the MNC
pellet resuspended in 5 ml of lysis buffer (6 M guanidine
hydrochloride and 0.2 M Na acetate, pH 5.5). Following this,
2.5 ml of 100% ethanol were added and the sample stored at
—20°C overnight. After centrifugation at 4°C for 30 minutes at
10 K rpm, the supernatant was removed, the RNAlprotein
pellet resuspended in urea buffer (6 M urea, 0.35 M Na chloride,
50 mM Tris pH 7.5, 1 mi EDTA and 0.2% SDS), and the
protein mixture extracted with water saturated phenol/chloro-
form (1:1). Total RNA was then alchohol precipitated; washed,
resuspended in diethylpyrocarbonate (DEPC) treated water,
and stored at —20°C for subsequent analysis. The concentration
of RNA was initially estimated by spectrophotometry (OD2).
Denaturing gel electrophoresis was subsequently performed to
confirm RNA integrity, using a known concentration of RNA
standard, to provide an accurate estimate of sample concentra-
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Table 1. Nucleotide sequences of oligonucleotide primers
Predicted
Probe 5' to 3' Oligonucleotide sequences size bp
IL-Ia Sense:
Anti-sense:
CTC AGT ACA TOC TCA GCA AAT GAC T
ACC AAC 000 AAG GTT CTG AAG AAG A
700
IL-1/3 Sense:
Anti-sense:
GTG AGT AGO AGA GOT GAG AGA GOC C
CTF GGT GAT GTC TGO TCC ATA TOA A
659
TNF-a Sense:
Anti-sense:
GTT GGA TGT TCG TCC TCC TCA CAG G
GGC TCC AGO CGG TGC TTG TTC CTC A
644
IL-6 Sense:
Anti-sense:
AAA AGA TGG ATG CTT CCA ATC TOG A
TGC TGA ATT TTT TAA AAT GCC ATT T
777
y-IFN Sense:
Anti-sense:
AAC CTT AAG AAA TAT TTT AAT GCA G
TAG TAA CTG GAT AGT ATC ACT TCA C
767
IL-2 Sense:
Anti-sense:
GGA AGC ACT TAA TTA TCA AGT CAG T
GTT TAT ATT TAT CAA ATT TAT TAA A
453
IL-4 Sense:
Anti-sense:
GAT CGT TAG CTT CTC CTG ATA AAC T
AGA TTC TAT ATA TAC TTT ATT TTA T
614
TGF-13l Sense:
Anti-sense:
CCG ACT ACT ACG CCA AGG AGG TCA C
AGO CCG GTT CAT GCC ATG AAT GGT G
499
.
TGF-f32 Sense:
Anti-sense:
CGA AGA GTA CTA CGC CAA GGA GOT T
GAT GAT GTA ATT ATT AGA TOG TAC A
416
GAPDH Sense:
Anti-sense:
(lOT CTT ACT CCT TOG AGO CCA TOT 0
ACC TCA ACT ACA TGO TTT ACA TOT T
898
cDNA synthesis was performed using a single stranded
cDNA synthesis kit ('Superscipt pre-amp': Gibco, BRL) ac-
cording to the manufacturer's instructions. Briefly, 1 g of total
RNA template was intially heated to 90°C for five minutes to
reduce secondary structure, quick-chilled on ice and then
incubated with 0.5 g of oligo dT primer at 70°C for 10 minutes.
After chilling on ice, this was incubated for 10 minutes at room
temperature followed by 50 minutes at 42°C with 200 units of
'Superscript' reverse transcriptase (RT), 500 M dNTP mix, 10
mM dithriothreitol, 20 mti Tris HCH pH 8.4, 50 mi KC1, 2.5
mM MgCI2 and 2 g of BSA in a 20 d final volume. The reaction
was terminated by heating to 90°C for five minutes, RNA
hybrids digested with 2 units of E. coli RNAse H at 37°C for 20
minutes. The cDNA product was then phenol extracted, etha-
not precipitated and resuspended in 40 pi of UV irradiated
DEPC treated water, and stored at —20°C for subsequent
analysis.
Multiple cytokine mRNA phenotyping using the polymerase
chain reaction technique. It is possible to analyze multiple
cytokine mRNAs from a single cDNA preparation using the
PCR technique, so-called mRNA phenotyping [38]. For this, 1
sl of the cDNA product was mixed with 1 unit of gelatine-free
TAC polymerase and reaction buffer containing 50 mri KCI, 10
mM Tris HCI, pH 9.0, 0.1% Triton x 100 (Promega, UK). In
addition, 200 M lithium dNTPs (Boehringer Mannheim Bio-
chemica), 20 sM of each primer pair (see below), and MgCI2
were added, the latter titrated independently to determine the
optimal concentration for each amplification product, ranging
from 2 to 10 LM. The final reaction made up to 50 .d with UV
irradiated DEPC treated water, and overlaid with mineral oil
(Sigma Chemicals). A master mix of PCR components was
made up for each set of reactions prior to addition of the cDNA
templates, to reduce variations in reaction components. To
reduce contamination, RT-PCR preparation was performed in a
designated part of the laboratory, and all stock solutions,
pipettes and tips regularly irradiated with UV light to break
down contaminant DNA structures. Synthetic 25'mer oligonu-
cleotide primers (a gift from ICI Pharmaceuticals, UK) were
designed from previously published human sequences using the
"Genebank" database (Table 1). These were oriented on sep-
arate exons so that the PCR product from cDNA amplification
could be distinguished from contaminating genomic DNA prod-
ucts according to their size. As a positive internal control of
RT-PCR efficiency, primers were derived for the constitutively
expressed "housekeeper" gene, glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). The reactions were performed using
a waterbath thermal cycler (Grant Ampligene) with samples
initially heated to 94°C for two minutes to reduce secondary
structure, followed by one minute at the optimal annealing
temperature for each set of primers [(Interleukin (IL)-la, IL-
1f3, IL-2 and IL-4: 55°C; tumor necrosis factor (TNF)-a, IL-6,
y-interferon (IFN) and GAPDH: 60°C], one minute at 72°C and
30 seconds at 94°C over 25 to 35 cycles. Ten microliters of the
PCR product were then analyzed by electrophoresis on a 1%
agarose gel, and visualized by ethidium bromide staining under
UV light.
Conditions for a semi-quantitative RT-PCR were determined
by establishing the minimal number of amplification cycles (25
to 35) for each set of primers which could be used to distinguish
LPS stimulated MNC mRNAs from unstimulated controls (Fig.
2). The range of cytokine mRNA products was detectable from
LPS stimulated but not from unstimulated MNCs at a given
cycle interval, with selective appearance of certain mRNAs in
some patients with IgA nephropathy (Fig. 3). Accordingly,
results were expressed as the percentage of samples in a
particular group of patients or controls with detectable mRNA
species, and provided an estimate of mRNA abundance relative
to the normal control group.
Two color immunofluorescence flow cytometry. Freshly iso-
lated MNCs were washed in ice-cold PBS with 0.2% sodium
Azide (PBS/A), and blocked with 20% normal human serum on
ice for 30 minutes. Subsequent incubations were performed
using 5 - i0 cells in 100 p1 final volume, on ice in two stages,
—a—
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Fig. 2. Semi-quantitative RT-PCR. cDNA was prepared from fresh
MNCs, and MNCs derived from whole blood stimulated with I sg/ml E.
coil LPS for 4 hours, and amplified over varying cycle intervals (15 to
35) using the PCR technique. In all cases, cytokine mRNAs were
detectable after fewer amplification cycles in LPS stimulated compared
with unstimulated control preparations, indicative of increased mRNA
transcipt levels.
each for 30 minutes with 20% human serum in PBS/A. Phyco-
erythrin (PE) conjugated mouse anti-human CD 14 monoclonal
antibody (Dako Ltd, UK), an IgG2a isotype, was used as a
specific monocyte marker, and a mouse anti-human DR mono-
clonal (Serotec, UK), an 1gW isotype recognizing a non-
polymorphic epitope, to analyse class II antigen expression. In
addition, an irrelevant IgGi isotype was used as a negative
control (Serotec), and antibodies titrated to an optimal working
concentration. After washing in PBS/A, an isotype-specific
fluorescein isothiocyanate (FITC) conjugated goat anti-mouse
IgGi secondary antibody demonstrating low cross reactivity
with the IgG2a isotype anti-CD 14 monoclonal antibody (Nordic
Immunologicals, UK) was used at the recommended working
concentration. Mter washing in PBS/A, samples were resus-
pended in 300 .tl of PBS/A and stored in the dark at 4°C prior to
analysis. Flow cytometric analysis was performed on a FACScan
flow cytometer using FAScan Research softwear (Beckton
Dickinson). During acquisition, data were collected on 2,500
events with a live gate set on CD 14 PE positive (monocyte)
ILi U cells. FITC fluorescence signals were represented graphically
on a logarithmic scale, and for data analysis as the percentage
DR positive cells (Fig. 4). MNC composition for RNA analysis
was determined by setting markers on CD 14 PE fluorescence
iLl I histograms to determine the percentage of monocytes in a given
sample.
Statistical analysis
Statistical analysis was performed using Stat-View SE soft-
wear (Apple Computer mc). Complete mRNA data were avail-
able for all samples, but for technical reasons, a small number
of immuno-flowcytometric studies was unsuccessful, and there-
fore excluded from the analysis. Multiple group testing was
performed by one way ANOVA, and where the likelihood of a
significant difference between groups was >95%, subsequent
inter-group anlysis conducted using a modified unpaired, two-
tailed t-test using within group mean square variance. Bonfer-
roni correction was used throughout to allow for multiple group
testing [39]; on this basis, data were considered significant
where P  0.05/N, and N = the number of tests performed. For
non-parametric data, Kruskal-Wallis followed by Mann-Whit-
ney U testing was performed. Chi-square testing was used to
compare proportions between groups (analysis of mRNA spe-
cies), with Fischer's exact test for small sample sizes.
Results
Mononuclear cell cytokine mRNA
Data are expressed as the percentage of samples from each
group with detectable mRNA transcripts, and are summarized
in Table 2. In addition, as there was no significant difference in
TGF-f2 mRNA detection between mild and moderate IgA nephropathy
groups for any of the cytokines tested (P> 0.05), data for these
groups have been pooled for statistical analysis.
TGF-131 mRNA was detected in 68% (24 of 35) of patients
with active, and 70% (7 of 10) inactive IgA nephropathy, but in
only 18% (3 of 17) normal (P = 0.0005, and P = 0.005,
respectively; chi-square test), and 27% (4 of 15) disease controls
(P = 0.28, vs. normal controls). IL-6 transcripts, on the other
hand, were detectable in 37% (13 of 35) of patients with active
IgA nephropathy compared with only 6% (1 of 17) normal
controls (P = 0.015), but none of the patients in remission, and
there was no significant increase in the disease control groups
20% (3 of 15) (P > 0.2, vs. normal controls). TNF-a mRNA was
detectable in 29% (5 of 17) of normal controls but only 7% (3 of
45) with IgA nephropathy (P = 0.015), and in 53% (8 of 15) of
disease controls. There was no significant increase in y-IFN
mRNA detection in IgA nephropathy patients with active
disease, 17% (6 of 35), compared with 6% (1 of 17) normal
controls (P> 0.25). However, 83% (5 of 6) of the patients with
active IgA nephropathy and detectable y-IFN mRNA also had
detectable IL-6 transcipts, compared with 28% (8 of 29) of those
without y-IFN mRNA (P = 0.01; Fischer's exact test), Detec-
tion of TGF-I32, IL-la, IL-1/3, IL-2 or IL-4 mRNAs was similar
TNFct
I L-6
1IFN
IL-2
IL-4
TGF-1
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Fig. 3. Analysis of cytokine mRNAs. The
optimal cycle interval (25 to 35) was chosen
for each set of primers to discriminate
between the majority of unstimulated normal
MNCs and mitogen stimulated cells.
Accordingly, the range of cytokine mRNAs
was detectable in LPS stimulated MNCs but
not in the normal controls; in contrast, there
was selective detection of certain cytokine
transcripts in some patients with IgA
nephropathy. GAPDH was used as an internal
control of RT-PCR efficiency.
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Fig. 4. Flow cytometric analysis: Class II antigen expression. Heter-
ogeneous staining for HLA-DR antigen expression on gated peripheral
blood monocytes (CD-l4 PE-positive MNCs) is illustrated with a
typical FLTC fluorescence histogram. The solid line represents staining
with the specific monoclonal antibody, and the dotted line, the isotype
control. Results are expressed as the percentage of CD- 14 postive cells
expressing total, or only high levels, of DR antigen after subtraction for
the irrelevant control antibody.
in all of the disease groups compared with the normal controls
(P > 0.25; chi square test), and there was no significant
association between IL-6, TNF-a or TGF-/3l mRNA detection
in patients with active IgA nephropathy (P 0.26; Fischer's
exact test).
Stratification of samples from both patients and control
groups into those with normal range, or increased urinary
protein excretion (< or  300 mg124 hr), and serum creatinine
levels (< or  120 /LM/liter) failed to demonstrate a significant
effect of these variables on the detection of MNC cytokine
mRNAs (P  0.1; chi square test; Fig. 5). In addition, serum
creatinines and urinary protein excretion rates were similar in
IgA nephropathy patients with or without detectable IL-6,
TNF-a or TGF-f31 transcripts (P> 0.1; Mann-Whitney U test).
Finally, there were no significant differences in MNC compo-
sition (the percentage of monocytes) between groups to account
for these differences in cytokine detection rates (P = 0.24;
ANOVA), with an overall mean (SD) of 20.4 (10.9)%.
Class II antigen expression by circulating monocytes
The combined mean (SD) percentage of monocytes express-
ing high levels of DR antigen was 8,8 (4.3)%, with a significant
difference between patient and control groups (P = 0.002;
ANOVA; Fig. 6). This was particularity marked in patients with
moderately active IgA nephropathy, 12.6 (4.8)%, compared
with normal controls, 6.7 (1.6)% (P < 0.001; t-test), but not in
those with mild IgA nephropathy, 8.6 (3.7)%, IgA nephropathy
remission, 8.1 (3.6)%, or the disease controls, 7.5 (5.2)% (P >
0.05; compared with normal controls). There was, however, no
significant difference between group variation in total DR
expression on circulating monocytes (P = 0.35; ANOVA), with
combined mean (SD) of 61.2 (21.8)% positive, and no difference
in forward light scattering profiles between groups (P =0.42;
ANOVA), indicating that these variations in phenotypic expres-
sion are not attributable to differences in cell size. Interestingly,
DR (high) expression was higher in IgA nephropathy patients
Control
+LPS
IgAN
IgAN
III
I
I
Ii (high)I
II
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Table 2. Detection of mononuclear cell cytokine mRNA in different clinical groups
Clinical groups
Percentage (number) of samples with detectable mRNA species
IL-a IL-i/3 TNF-a IL-6 y-IFN IL-2 IL-4 TGF-/31 TGF-132
Normal controls 0% 12% 29% 6% 6% 12% 12% 18% 29%
N = 17 (0) (2) (5) (1) (1) (2) (2) (3) (5)
Disease controls 0% 13% 53% 20% 13% 0% 0% 27% 33%
N = 15 (0) (2) (8) (3) (2) (0) (0) (4) (5)
IgA nephropathy
remission 0% 0% 0% 0% 0% 0% 0% 70% 20%
N = 10 (0) (0) (0) (0) (0) (0) (0) (7)b (2)
Active disease
Mild 0% 14% 9% 38% 14% 0% 0% 76% 24%
N = 21 (0) (3) (2) (8) (6) (0) (0) (16)b (5)
Moderate 7% 21% 7% 36% 21% 21% 0% 57% 36%
N = 14 (1) (3) (1) (5) (3) (3) (0) (8) (5)
Data are expressed as the percentage of samples within each group with detectable mRNA species. Disease activity in patients with IgA
nephropathy was stratified according to urinary red cell excretion rates: <8/mm3: remission; 8—100/mm3:mild active; > lOO/mm3:moderately active.
None of the patients had macroscopic hematuria.
a indicates comparison with normal controls, P < 0,05; b P < 0.005 (chi-square test)
with detectable IL-6 mRNA, 12.4 (5.l)%, N = 12, versus those
with undetectable mRNA, 8.8 (3.8)%, N 27, (P 0.02;
t-test), and in those with detectable -IFN mRNA, 14.3 (6.3)%,
N = 6, versus 9.2 (3.7)%, N = 33 (P = 0.008), but there was no
correlation in class II antigen expression with the detection of
TNF-a or TGF-/31 mRNAs.
Discussion
The functional significance of abnormalities in cytokine ex-
pression has been investigated in a number of experimental
models of glomerulonephritis. Manipulation of mononuclear
cell infiltrates [17—19] and cytokine expression using blocking
antibodies [26—28] or exogenous administration of recombinant
cytokines [29—30] has demonstrated the central importance of
both the infiltrating inflammatory cell, and intrarenal expression
of cytokines in the modulation of both the acute and chronic
glomerular responses to immune injury. Furthermore, studies
using the remnant kidney model of progressive glomerular
sclerosis demonstrate that infiltrating monocytes [40] and ab-
normal tissue cytokine expression [41] may also be of impor-
tance in controlling excessive scar tissue formation even in the
absence of direct immunological injury. In human IgA nephrop-
athy there is also an accumulation of intrarenal inflammatory
cell populations [15, 161 and abnormal renal tissue expression of
cytokines [31, 32, 421. Based on the experimental evidence
therefore, while the deposition of nephritogenic autoantibodies
and other immunoglobins likely to be involved in one limb of
the disease process [6, 7], these findings also suggest an
important role for dysregulated tissue cytokine expression and
mononuclear cell inifitration in both the initation and perpetu-
ation of renal pathology in this condition.
Abnormal cytokine production by circulating and tissue
infiltrating MNCs has also been implicated in the pathogenesis
of a number of autoimmune diseases characterized by poly-
clonal B cell activation and selective tissue damage, including
rheumatoid arthritis [43, 44], and SLE [45—47]. IgA nephropa-
thy is characterized by polyclonal B cell activation, with
elevated levels of circulating IgA 1 [3] associated with poly-
clonal expansion ofigAl bearing B cells in the bone marrow [4],
in addition to episodic secretion of polymeric IgA [2], and IgG
autoantibodies [6, 7], but there are limited published data on the
pattern of mononuclear cytokine expression in this condition.
Furthermore, the study of cytokine expression systems in vivo
is complicated by the critical dependance of a tissue response
on the balance, or network, of regulatory factors to which the
cells are exposed [48]. As a result, the study of isolated
cytokines is unlikely to give a realistic picture of pathogenic
mechanisms in patients with IgA nephropathy, and for this
reason we have simultaneously analyzed a panel of interacting
lymphocyte and monocyte derived cytokines in peripheral
blood MNC preparations. To do this we have used the PCR
technique as a screening procedure to detect multiple cytokine
mRNA phenoptypes, as previously described [38]. This has the
advantage of being simple to perform, avoiding the requirement
for radioisotopic hybridization with Northern blot, or Si nude-
ase analysis, and may be conducted on the small quantities of
RNA obtained from fresh MNC preparations. In addition, while
the competitive PCR technique may be used to provide an
accurate measure of cellular mRNA expression [49], it involves
the generation of mutant cDNA or RNA constructs, and the
requirement for multiple RT-PCR reactions to quantify specific
mRNA expression, which would be inappropriately complex
and time consuming for use as a screening procedure.
Several steps were taken to apply this technique as a semi-
quantitative analysis. cDNA preparations were performed us-
ing known amounts of total RNA, accurately quantified by
denaturing gel electrophoresis against an RNA standard. cDNA
preparations were subsequently amplified over specified num-
bers of cycles for each set of primers, with co-amplification of
GAPDH mRNA to control for variations in the efficiency of the
cDNA synthesis reaction. In addition, we used master mixes of
reaction components to minimize variations between individual
PCR preparations. In view of the subjective nature of visual
assessment of PCR products under ultraviolet light, no attempt
was made to quantify the intensity of staining with ethidium
bromide, and individual samples were scored as having detect-
able or undetectable PCR products for a given cytokine mRNA.
This approach represents a simplified modification of an estab-
lished PCR technique [50], and while it does not provide an
absolute measure of mRNA abundance, it does enable a relative
1304 de Caestecker et a!: Cytokine networks in IgA nephropathy
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comparison of cytokine transcipt levels between patient and
control groups. Finally, specificity of the amplification products
was determined by gel electrophoresis, with the detection of
rnRNA products of predetermined size, distinct from genomic
fragments. While it is possible that these represent non-specific
PCR amplification products, it is highly improbable that all of
the primers tested should have reproducibly amplified non-
specific products corresponding precisely to the predicted sizes
from mRNA sequence data, by chance alone. For this reason,
we have avoided the additional complexity of Southern blot
hybridization or restriction enzyme digestion experiments to
confirm the specificity of our PCR products.
Using this technique, we were able to detect changes in
TGF-f31, !L-6 and TNF-a mRNA expression in peripheral
Fig. 5. Detection of MNC mRNA species
according to serum creatinine levels, and
urinaly protein excretion rates. Samples from
both patient and control groups were stratified
according to the levels of serum creatinine[< () or  () 120 ILM/hter], and urinary
protein excretion [< () or  () 300 mg/24
hr], and results expressed as the percentage
within each new grouping with detectable
mRNA species, as shown. There were no
significant differences between groups for any
of the cytokine transcripts tested (P = 0.1; chi
square test).
blood MNCs from patients with IgA nephropathy. This was not
associated with a generalized increase in cytokine mRNA
expression, as there was no significant alteration in TGF-/32,
IL-la, IL-l/3, y-IFN, IL-2 or IL-4 detection. The changes in
TGF-f31 and TNF-a mRNA expression appeared to be specific
for patients with IgA nephropathy as there were no parallel
changes in the disease control group, comprised of eight pa-
tients with chronic renal failure of "non-immune" etiology, and
seven with mesangial proliferative glomerulonephritis associ-
ated with 1gM deposits. Differences in IL-6 mRNA detection
were less clear cut. While significantly increased in patients
with active IgA nephropathy (37%, 13 of 35) compared with the
normal controls (6%; 1 of 17), 20% (3 of 15) of disease controls
also had detectable transcripts. This indicates that while IL-6
//
I//////// iiC)aU)
z
E
a)
a)V
a)
a)
C)
a)0
60
50
40
30
20
10
0
60
50
40
30
20
10
0
IL-la lL- TNF-a IL-6 yIFN IL-2 IL-4 TGF-J31 TGF-2
B Serum creatinine
IL-la lL-3 TNF-ct lL-6 ylFN IL-2 IL-4 TGF-1 TGF-132
de Caestecker et a!: Cytokine networks in IgA nephropathy 1305
Fig. 6. Class II antigen expression. The
percentage of monocytes (CD-14 PE positive
MNCs) expressing high levels of DR antigen
was determined by two-color
immunoflorescence flow cytometry, as
described in Methods. There was a significant
difference between groups, P = 0.002
(ANOVA); (—) represents mean values for
each group; * indicates comparison with
normal controls, P < 0.001 (t-test).
mRNA detection was increased in patients with active IgA
nephropathy these changes may not reflect a specific pathoge-
netic process in this disease. On the other hand, these changes,
and the differences in TGF-/31 and TNF-a mRNA expression,
were independent of other clinical parameters of renal injury,
including serum creatinine and urinary protein excretion rates,
evidence that these abnormaiities are, in fact, likely to repre-
sent specific immunoregulatory defects in patients with IgA
nephropathy. Finally, our empirical stratification of IgA ne-
phropathy disease activity according to urinary red cell excre-
tion rates appears to have been validated as there was a clear
distinction in cytokine mRNA detection and monocyte class II
antigen expression in those patients with higher grades of
urinary blood loss. This corroborates clinical data from
Nicholls et al [51] suggesting that urinary erythrocyte excretion
is an important prognostic factor in patients with IgA nephrop-
athy. Urinary protein excretion, which has been used as a
clinical marker of disease activity in glomerulonephritis, corre-
lates with other clinicopathological indicators of disease chro-
nicity [51, 52], so that its use as a gauge of acute IgA disease
activity may be invalid.
Enhanced expression of TGF-pl mRNA by peripheral blood
MNCs has not previously been reported in IgA nephropathy.
Unlike the other cytokines, this was up-regulated in all patient
groups, irrespective of urinary red cell excretion rates. This
suggests that increased expression of TGF-/31 mRNA is unre-
lated to acute disease activity. Furthermore, these changes in
TGF-/31 expression were not associated with an up-regulation
in TGF-32 mRNA detection. This is of interest, as this cyto-
kine, while demonstrating marked structural and functional
homology to the TGF-J31 isoform, is under separate transcip-
tional control and its expression has been shown to be indepen-
dantly regulated in different cell types in vitro, and in a number
of different settings in vivo [53J. The significance of this differ-
ential regulation in TGF-j3 isoforms is, however, unknown.
Given the important role of TGF-$1 in the modulation of
glomerular matrix and scar tissue formation [27], the fact that
mesangial expression of the cytokine may be autoinduced [25],
and the potential role of TGF-/3 in IgA switching of B cells [54],
we speculate that these changes in MNC mRNA expression
could play a central role in the pathogenesis of IgA nephropa-
thy. However, it is well-recognized that TGF-f3 mRNA expres-
sion can be dissociated from active protein secretion [55], so
that these data must be interpreted with caution, and further
work is in progress to elucidate the significance of these
findings.
IL-6 mRNA was up-regulated in a proportion of patients with
active disease. These data confirm our preliminary findings of
enhanced spontaneous IL-6 protein secretion by isolated mono-
cytes [12], and from Ranierei et al using peripheral blood MNC
preparations [13] from patients with active IgA disease. The
discrepancy with data from Lai et al [11], who failed to
demonstrate any significant increase in IL-6 secretion by cul-
tured MNCs from these patients, probably reflects patient
selection and their use of PHA as a mitogen in all the experi-
ments, as this has been shown to mask changes in spontaneous
cytokine release by cultured PBMNCs in this condition [13].
Furthermore, their MNC preparations were depleted of mono-
cytes, which are the main cellular source of IL-6 in human
peripheral blood [56], with less than 4% CDI lb positive cells on
immunofluorescence analysis, compared with a mean (SD) of
20.4 (10.9)% using CD 14 as a monocyte marker in our study.
IL-6 itself is a highly pleiotropic cytokine with effects on a
range of different target cells. Of particular relevance in this
context is its central role in the control of B cell differentiation
and immunoglobulin secretion [14], underlying its implicated
role in the pathogenesis of rheumatoid arthritis [43,44] and SLE
[45—47]. Furthermore, it may also have an indirect effect on IgA
subclass secretion through selective stimulation of IgA bearing
gastrointestinal B cells [57], which may be of importance in IgA
nephropathy. IL-6 is also an autocrine growth factor for cul-
tured mesangial cells [21], so exogenous secretion of this
cytokine by infiltrating glomerular monocytes may rapidly
up-regulate endogenous mesangial expression by paracrine
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mechanisms. Indeed, there is evidence of increased IL-6 ex-
pression in the glomerulii [31, 32], and urine [33, 34] of patients
with mesangial proliferative IgA nephropathy. Furthermore,
experimental evidence using passively administered recombi-
nant cytokines in a murine model of IgA nephropathy, suggests
that it may have direct effects on glomerular structure and
function in disease states [30].
Down-regulated TNF-a mRNA expression in patients with
IgA nephropathy is more difficult to explain. TNF-a mRNA is
rapidly up-regulated following ex vivo manipulation of mono-
cytes [36], so that it was not unexpected to detect PCR products
for this cytokine in a 29% of normal, and 53% of disease
controls. However, only 7% of patients with IgA nephropathy
had detectable TNF-a transcipts. The pathological significance
for this is uncertain, but there are parallels for this in patients
with SLE nephritis in whom freshly isolated PBMCs have been
shown to have a diminished capacity to express TNF-a [45],
and in the (NZB*NZW) ft murine model of SLE nephritis in
which there is also down-regulation of TNF-a expression,
glomerular injury may be abrogated by the systemic infusion of
the recombinant cytokine [58]. In our patients, these changes in
TNF-a mRNA may result from an inhibition of cytokine
transciption during cell separation by MNC derived IL-6, since
exogenous IL-6 has been shown to suppress TNF-a expression
by monocytes [59]. Alternatively, there may be "desensitiza-
tion" of TNF-a expression following repeated exposure to an
unidentified exogenous stimulus in patients with IgA nephrop-
athy, a process which has been described following continuous
in vitro stimulation of monocytes with lipopolysaccharide [60].
We were also able to demonstrate an association between
yIFN and IL-6 transcript detection in some patients with IgA
nephropathy, suggesting an interaction between a T-cell,
y-IFN, and a predominantly monocyte derived cytokine, IL-6
[56], in these patients. Indeed, there is in vitro evidence that
exogenous y-IFN may enhance monocyte IL-6 expression [35],
and in patients with IgA nephropathy, PBMNCs have been
shown to secrete increased amounts of y-IFN into culture
supernatants following mitogen stimulation [11]. Our failure to
detect changes in other T cell-derived cytokines, however,
conflicts with previously published data suggesting that there is
up-regulation of IL-2 expression by PBMNCs from patients
with IgA nephropathy [10, 111. This discrepancy may reflect
differences in disease activities between studies, particularly
the former in which there is no description of the patients'
serum creatinine, urinary protein, or urinary red cell excretion
rates [10]. In the latter paper, MNC preparations were highly
enriched for lymphocytes [11], so that our failure to detect
significant changes in T cell-derived cytokine mRNAs may
simply reflect the lower numbers of lymphocytes in our prepa-
rations.
Finally, there was an up-regulation of class II antigen expres-
sion on circulating monocytes, confirming data from Rocatello
et at [61], and suggesting an association between monocyte
activation and the generation of abnormal cytokine mRNA
phenotypes in these patients. The pattern of class II expression,
with increased percentages of monocytes with high levels of DR
antigen rather than a change in the total numbers of DR positive
cells, parallels changes decribed in vitro following stimulation
with y-IF'N [62]. Our data also demonstrate an association
between high DR expression on circulating monocytes, and the
detection of MNC y-IFN, providing further evidence that that
this T cell-derived cytokine may be involved in the generation
of activation phenotypes in patients with IgA nephropathy.
Having said that, the significance of these findings in patients
with active IgA nephropathy is uncertain, given the heteroge-
neity of monocyte DR antigen expression in the different patient
and control groups. However, like the IL-6 mRNA expression
data, it suggests that within the group of patients with moder-
ately active nephropathy, there are some who may well have a
biologically significant increase in DR expression. In a cross
sectional study, this is compatible with a transient up-regulation
of surface antigen expression on circulating monocytes, which
may only be increased in a proportion of the patients at any one
time point.
In conclusion, we have demonstrated increased expression of
MNC cytokine mRNAs in patients with IgA nephropathy using
the PCR technique to analyze multiple mRNA phenotypes.
There was an up-regulation in TGF-J3l and IL-6 mRNA, inde-
pendent and dependent, respectively, on disease state with
down-regulated TNF-a detection, and these were associated
with enhanced class II antigen expression on circulating mono-
cytes. Together these data suggest a selective activation of
circulating MNCs which could account at least in part, through
the secretion of relevant cytokines in lymphatic and renal tissue
infiltrates, for the immune system and renal tissue abnormalities
seen in patients with IgA nephropathy.
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